RegeneRx jumps on positive preclinical study dataNEW YORK (AP) - Shares of RegeneRx Biopharmaceuticals Inc. surged to a new year high Tuesday after the company reported positive data from a preclinical study of its prospective multiple sclerosis treatment RGN-352.RegeneRx said the drug improved the recovery of nerve function when it was tested on animals.In afternoon trading, shares of the Bethesda, Md.-based company jumped 32 cents, or 39 percent, to $1.14. Earlier they traded as high as $1.95, eclipsing a previous 52-week high of $1.82 set in January. LINK
MYMAN got into RGN last month.
It is back to it's .85, My Man! Are you still holding it or did you get your profit yesterday?
ReplyDeleteNah, I didn't sell. I'm willing to wait see what happens down the road, my man. RGN has 4 drugs in the pipeline and my investment that not big, only 800 shares so I'm just gonna forget about it for a while.
ReplyDelete